Pharma

Your Article Summary

See Latest Articles

Glivec approved in EU as first post-surgery therapy to reduce risk of cancer returning in patients with aggressive gastrointestinal tumors
Novartis, 05/08/09

Glivec (imatinib) received approval from the European Commission to become the first and only treatment available in Europe to reduce the risk of recurrence in adult patients who are at significant risk of relapse following surgery to remove gastrointestinal stromal tumors.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals